Crelosidenib

A pharmaceutical drug used in cancer treatment

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002548 | IUPAC_name = (3R)-3-(1H-Indol-3-yl)-1-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]piperidin-2-one | image = Crelosidenib.svg | image2 = | width = 200 | alt = | tradename = | synonyms = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | DrugBank = DB12345 | ChemSpiderID = 123456 | UNII = | KEGG = | ChEMBL = 1234567 | C=24 | H=28 | N=4 | O=1 | smiles = | InChI = | InChIKey = }}

Crelosidenib is a pharmaceutical compound that functions as a dual inhibitor of the tyrosine kinase enzymes FLT3 and KIT. It is primarily investigated for its potential use in the treatment of certain types of cancer, particularly acute myeloid leukemia (AML).

Mechanism of Action

Crelosidenib works by inhibiting the activity of the FLT3 and KIT tyrosine kinases. These enzymes are involved in the signaling pathways that regulate cell proliferation and survival. In many cancers, including AML, mutations in the FLT3 gene lead to uncontrolled cell growth. By inhibiting these kinases, crelosidenib can potentially slow down or stop the proliferation of cancer cells.

Clinical Development

Crelosidenib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with AML and other malignancies. The drug is being tested both as a monotherapy and in combination with other chemotherapeutic agents. Early-phase trials have shown promise, with some patients experiencing partial or complete remission.

Pharmacokinetics

The pharmacokinetic profile of crelosidenib includes its absorption, distribution, metabolism, and excretion. It is administered orally, and studies are ongoing to determine the optimal dosing regimen. The drug is metabolized primarily in the liver, and its metabolites are excreted through the kidneys.

Side Effects

As with many cancer therapies, crelosidenib can cause a range of side effects. Common adverse effects include nausea, fatigue, and hematological abnormalities such as neutropenia and thrombocytopenia. More serious side effects may include liver toxicity and cardiac issues, which require careful monitoring during treatment.

Research and Future Directions

Research on crelosidenib is focused on understanding its full potential in cancer therapy. Ongoing studies aim to identify biomarkers that predict response to treatment and to explore its use in other cancers beyond AML. The development of resistance to FLT3 inhibitors is a significant challenge, and combination therapies are being investigated to overcome this issue.

Related Pages

• Tyrosine kinase inhibitor
• Acute myeloid leukemia
• Cancer treatment